Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07787169). This is a study registration, not published results. Lead sponsor: Eli Lilly and Company. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 179 participants (ESTIMATED). Conditions: Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers. Interventions: DRUG: LY4405094; DRUG: LY4405094; DRUG: Placebo; DRUG: Placebo; OTHER: Florbetapir F18; OTHER: Florbetaben F 18. Primary outcome measures: The number of participants allocated to each substudy , Baseline up to Day 160. Brief summary: The purpose of this Master Protocol is to support multiple studies looking at safety and tolerability of different drugs in healthy participants and participants with Alzheimer's disease, and if they remove clumps of protein (amyloid plaque) in the brain in participants with Alzheimer's Disease. Participants will enroll into either A1D-MC-AT01 (NCT07787182) or A1D-MC-AT02 (upcoming).